DaVita Inc. (DVA) Earnings Call Transcript & Summary

October 29, 2020

New York Stock Exchange US Health Care Health Care Providers and Services earnings 56 min

Earnings Call Speaker Segments

Jim Gustafson

executive
#1

Thanks for joining us for this third quarter conference call, and we're glad you continue to take an interest in our company. This is Jim Gustafson speaking — I serve as Vice President of Investor Relations — and with me today are our CEO, Javier Rodriguez, and our CFO, Joel Ackerman. I'd like to point out that on this call we might make forward-looking statements as defined under federal securities laws. Each of those statements carries known and unknown risks and uncertainties, and because of them actual results may end up differing materially from what the forward-looking statements describe. If you'd like more information about those risks and uncertainties, take a look at our third quarter earnings press release and our SEC filings, which include our latest annual report on Form 10-K along with our later quarterly reports on Form 10-Q. The forward-looking statements we make rest on information we have right now, and we have no intention — and no obligation — to revise them, unless the law requires it. Also, a reminder: some of the financial measures we'll talk about on this call are non-GAAP. You can find a reconciliation between those non-GAAP measures and the closest comparable GAAP financial measures in our earnings press release, which has been submitted to the SEC and is posted on our website. At this point I'll hand the call over to Javier Rodriguez.

Javier Rodriguez

executive
#2

Thanks, Jim, and good afternoon to all of you. We appreciate you being here as we go over the financial results for our third quarter. Nine months have now passed since the pandemic began, and one fact stands out: the caregivers on our team are devoted to looking after our patients. Thanks to that team, the business is doing well even with the disruptions caused by the pandemic, wildfires, and hurricanes. I've mentioned this previously, and it deserves saying again: being part of DaVita and working alongside our 65,000 teammates fills me with enormous pride, since they put in such hard effort to give our patients care that sustains life. Our people are what make the business resilient when faced with so many difficult external factors. Throughout these difficult times, we keep our attention on our patients and on developing capabilities that will improve their care and their experience going forward. Even today, an excessive number of patients feel caught off guard when they begin dialysis, which affects their capacity to adjust their lifestyle and afterward select the modality that suits them best; we partner with patients who have chronic kidney disease, or CKD, to assist them in grasping how to remain healthy, slow the progression of kidney disease, pursue transplantation, and assess various treatment options. One key factor in preventing a surprise start is education. We're thrilled to have hit a milestone during this quarter by educating 200,000 people via our Kidney Smart program, an education program for CKD that comes at no cost. Throughout the pandemic, every Kidney Smart class has been moved to a virtual format, and engagement with CKD patients remains high. The program delivers healthy results, since people who attend a Kidney Smart class are six times more likely to begin dialysis at home, have 38% fewer missed treatments during their first 90 days on dialysis, and experience 30% fewer hospitalizations. Now to the quarterly results. Q3 proved to be another strong quarter for our company. Total revenue arrived largely in line with expectations. Although volume growth was weaker than historical levels because of the impact of COVID, total revenue stayed strong thanks to the year-to-date improvement in revenue per treatment. Our costs landed significantly below our forecast owing to a lower COVID impact this quarter and continued strong cost management. Looking ahead, my confidence in the strength of our business model, along with our earnings and free cash flow growth, remains firm. Because of our strong performance over the past year, we're ahead of the plan we discussed at last year's Capital Markets Day, both financially and strategically. On the financial side, we're ahead of the expected adjusted earnings per share guidance we shared both in 2020 and 2022. Today, we are once again raising our 2020 adjusted earnings per share guidance range to $7.35-$7.60. Over the past year, we've managed to achieve operating margin increases and share purchases faster than expected; on top of that, we've also brought down our debt cost in line with what we expressed at Capital Markets Day. Looking ahead, we're confident in our ability to deliver continued capital-efficient growth from 2020 levels over the next few years. To put a number on that, our expectation is that we can achieve average yearly growth in adjusted EPS within the low double digits. I'd like to point out that we're doing this even as we keep putting money into innovation, adding new capabilities, and making our platform stronger. On the strategic front, we've achieved concrete progress in widening and deepening what we can do clinically and operationally, powered by our digital transformation across a number of areas. Our view is that these platform capabilities will give us a competitive edge, centered on our patients, nephrologist partners, and payer partners. We also see a way to leverage these capabilities to raise both the quality and the value of care we provide to patients throughout the healthcare delivery system; for instance, we're tailoring care for patients along the kidney care continuum by drawing on proprietary systems we've spent years developing and on partnerships with industry leaders such as Epic, Cerner, Salesforce, and Google. There's still more work ahead of us to bring our strategy to fruition. We're starting to realize gains from these tools through AI-driven models that customize dosing for certain therapeutics, forecast patients' clinical status, and assist in preventing hospitalizations, foresee patients who might discontinue home therapy, and spot CKD Stage 4 patients likely to advance rapidly to ESRD and help prevent unplanned dialysis starts. As we put these tools and information into the hands of nephrologists and our caregivers, we foresee three major benefits. First, making possible a best-in-class patient experience, providing individualized care at scale. Second, making it possible for our physicians to achieve industry-leading clinical outcomes. Third, bringing down the total cost of care for kidney care populations by preventing disruptions stemming from preventable hospitalization stays and changes in modalities that aren't clinically driven; we're also achieving strategic progress in our move toward value-based payment models. Across the last decade, we've established capabilities and real-world experience in managing the total cost of care for ESRD patients via our partnerships and the distinctive relationships and access we have to over 200,000 dialysis patients. We've created a care model customized to the particular needs of dialysis patients and have brought it to bear across a range of value-based payment models, among them shared savings and full capitation. Our conversations with payers regarding the use of value-based arrangements to align incentives and generate better outcomes have picked up speed in recent quarters. When it comes to government, we're giving careful thought to the value-based arrangement models that CMS has developed; on the commercial side, we keep contracting for pay-for-performance models covering both ESRD and CKD patients. We're additionally capitalizing on the anticipated growth of Medicare Advantage within the ESRD population to speed up discussions with MA plans regarding new payment models; we're enthusiastic about the momentum behind value-based care, and we're ready for chances to partner with government and commercial payers; our belief is that our existing capabilities, extensive experience, and national scale provide us with a superior platform for delivering value to our partners, patients, and payers. At this point, I'll hand things to Joel, and he'll go deeper into our financial results and outlook.

Joel Ackerman

executive
#3

Thanks, Javier. For Q3, we again delivered strong financial results at DaVita. We beat what was expected by a wide margin, thanks to underlying business strength plus gains from certain one-time tailwinds. I'll begin with Q3, then discuss Q4 guidance along with some views on the longer term. Adjusted operating income came in at $438 million for the quarter, down roughly $24 million from Q2's adjusted OI on a sequential basis. Two factors mainly explain this decrease. The first is the California ballot measure. During Q3 we put about $66 million toward the industry effort to defeat Prop 23, matching what we anticipated for the full year's ballot initiative cost impact of roughly $0.50 per share. The second is that COVID gave us an OI improvement of about $50 million in Q3 versus Q2. On the prior call, I mentioned an estimated $20 million-$30 million in net COVID-related costs for Q2; we thought Q3's COVID effect would look much like Q2's. Instead, we had a net positive impact of roughly $20 million-$30 million this quarter, which is a $50 million favorable swing from last quarter at the midpoint of those ranges. Lower direct COVID costs drove this, while the offsets we saw in Q2 were nearly unchanged. Once you adjust for those two items, the business's underlying earnings power stayed solid in Q3 and in line with Q2. Going forward, COVID continues to carry substantial uncertainty. Forecasting how the pandemic will unfold remains hard, and the way it affects NAG, commercial mix, and operating expense leaves a broad set of possible outcomes for Q4 and for 2021. Given how well Q3 went, our expectation of another solid underlying result in Q4, and room for a range of possible COVID-related costs, we're revising 2020 guidance as follows. Our 2020 adjusted operating income margin guidance moves up to 15.3%-15.6%. Our 2020 adjusted EPS guidance moves up to $7.35-$7.60. Our 2020 free cash flow guidance moves up to $1.1 billion-$1.25 billion. Let me add a few points to what Javier said regarding our longer-term outlook for low double-digit adjusted EPS growth. First, we presently anticipate that this growth will come from adjusted operating income growth in the low to mid-single digits, with the remainder from disciplined capital allocation and lower debt costs. Second, this leaves out any major uncertain events, like changes to federal tax rates or repeal of the ACA. Third, we view this as the earnings and cash flow potential of the business in a typical year, though any single year's performance could differ materially from these trends. For 2021, we intend to provide more detail on our next earnings call. That said, I'll highlight some headwinds and tailwinds that might arise. First, we expect the absence of ballot initiative costs to be a tailwind. Moving on, should California's Proposition 23 be approved and put into effect, we anticipate substantial costs and operational difficulties in meeting its mandates during 2021. Number three, it's not possible to forecast COVID, even though right now we anticipate it might represent a considerable headwind in the coming year. Because the adverse effect on NAG builds up as time goes on, we would anticipate that our treatment volume growth compared with the prior year will stay suppressed, even while the immediate effect on our patients lessens; we also anticipate losing the advantage of the Medicare sequestration suspension and expect that certain other offsetting factors, such as reduced health benefit expenses and travel costs, will swing back. So far, the effect on commercial enrollment has been smaller than anticipated, though COVID's longer-term economic consequences might lead to uneven worsening during 2021. Additionally, we are observing higher unit costs for PPE, which will probably act as a headwind in 2021. In our view, the single possible tailwind stemming from COVID would be a decrease in certain direct costs we absorbed in the pandemic's early phase. Then, although the calcimimetics contribution ought to be fairly level compared with last year, we will stop labeling it non-recurring since it is now a lasting part of our run rate. Additional variable factors involve possible shifts in Medicare Advantage enrollment and possible expenses tied to launching value-based care contracts. A handful of other points. From our Q2 earnings call until now, we bought back roughly 10 million shares of our common stock, meaning our share count today stands at about 112 million. When modeling your EPS, you must also factor in dilution from outstanding equity awards, which amounted to roughly three million shares in Q3. Lastly, because of reduced LIBOR rates and interest expense tied to debt financings finished this year, we anticipate quarterly debt expense of about $65 million during Q4. With that, operator, kindly open the line for questions.

Kevin Fischbeck

analyst
#4

Thanks, that's great. I suppose I'll begin with what you said about guidance. I appreciate the negative and positive factors you mentioned, which, as I understand it, really pertained to 2021. Let me just confirm: within your EPS growth in the double digits, you've built in a sensible estimate covering all of those negative and positive factors as part of that assumption of double-digit expansion across the coming two years.

Joel Ackerman

executive
#5

That's right, Kevin, we did. One thing I'd note is that the EPS guidance spans multiple years; it isn't aimed at next year in particular. Yes, we have factored in the negative and positive factors we identified.

Kevin Fischbeck

analyst
#6

The starting point sits at $7.35 to $7.60. During the quarter, you brought up several one-time items. I simply want to confirm that your point is this $7.35-$7.60 serves as the foundation for applying that growth rate.

Joel Ackerman

executive
#7

Correct, I'd say this year works well as that base.

Kevin Fischbeck

analyst
#8

All right. When it comes to MA, I don't believe you actually called it either a headwind or a tailwind. You sort of framed it simply as an unknown. Could you share a bit about how you see MA developing, plus anything new on the Humana contract?

Joel Ackerman

executive
#9

Of course, Kevin. Several forces are at play there, so I'll take them individually. First, our view hasn't changed that MA enrollment will build up slowly, which matches what we told you in prior quarters. Second, open enrollment has only just begun, and there's nothing we can report yet. Even if more time had passed, our visibility is quite limited, so we'll hold off until essentially January, when the figures come in. Finally, on Humana, a few points come to mind. Typically, we avoid discussing specific accounts. With this one, because it became public, I'll offer a few remarks. The larger issue we ought to tackle is whether MA is about to produce a huge lump or surge of renegotiations. That is not the case. Humana is the one exception. Across the MA book, we hold comprehensive contracts, so we're positioned well, and most of our portfolio remains under contract past 12 months. Regarding Humana in particular, they gave us notice of a non-renewal. We're having a highly constructive conversation with them about a risk deal, and as you're aware, risk deals require time. Talks with them are ongoing, and we're hoping to resolve the issues.

Kevin Fischbeck

analyst
#10

All right, that's good. I suppose this will be my final inquiry at this point. During the quarter, you noted that pricing on the commercial side acted as a headwind, despite the fact that, as I understand it, it served as a tailwind for the year so far. What took place during the quarter, I suppose? Should we consider it a one-off event, or is there anything else we ought to be contemplating as we move forward?

Javier Rodriguez

executive
#11

Yes, Kevin, this is far more along the lines of a one-off event. My suggestion would be to keep your attention on the complete year-over-year comparison instead of concentrating on any single quarter.

Kevin Fischbeck

analyst
#12

All right, so you wouldn't anticipate that affecting Q4 too?

Javier Rodriguez

executive
#13

No.

Kevin Fischbeck

analyst
#14

All right, great. Thanks.

Javier Rodriguez

executive
#15

Thank you.

Andrew Mok

analyst
#16

Hello there, and good afternoon. I appreciate you taking the question. Javier, during May you said the highest point of joblessness counts for more than how the rebound takes shape; it's now late October, and that peak jobless figure — at least the headline one — has probably already occurred. In what way does that top level, together with the internal information you're seeing regarding COBRA enrollment, influence how you view the possible effect that commercial mix could have on your company during 2021? Thank you.

Javier Rodriguez

executive
#17

Thanks, Andrew. I can't say when unemployment will reach its highest point. From what our patients have shown us, they've displayed remarkable resilience in their efforts to hold onto both their employment and their coverage; regarding our mix, we feel quite good about the current situation compared with a couple of quarters back — in other words, it has remained stable. Naturally, we can't predict where the pandemic is headed or what direction the labor markets will take. That's the situation as of today. We find ourselves in a better spot than I had anticipated a quarter ago.

Andrew Mok

analyst
#18

Understood, that's useful. And then, could you assist us in putting a number on how treatment growth has been affected by two factors — deaths among patients due to COVID, and a slowdown in where referrals come from? Thank you.

Joel Ackerman

executive
#19

Of course, Andrew. Joel speaking. That's one I'll handle. When you consider how COVID has affected NAG, we really think about five items. Deaths, transplants, treatments that were missed, acutes, and new patients beginning. Looking back at the prior quarter, deaths represented the largest headwind; transplants and missed treatments, meanwhile, were modest tailwinds, while acutes and new starts were modest headwinds. The four items besides deaths have genuinely worked their way through — they've either gotten smaller or flipped direction. The way we see it at present, things could certainly shift, of course, but for the most part those items aren't working their way through for NAG from here on. Mostly, it comes down to deaths.

Andrew Mok

analyst
#20

Understood. Appreciate that context.

Javier Rodriguez

executive
#21

Thanks, Andrew.

Javier Rodriguez

executive
#22

Hi there, Justin.

Justin Lake

analyst
#23

Thank you. Hello. My first question is about the factors that could help or hurt us in 2021. When considering COVID, you mentioned it might act as a sizable drag in the coming year, yet the absence of advocacy expenses could balance that out. At this point, do you view those as roughly even, a net negative, or a net positive, without getting into too much detail?

Joel Ackerman

executive
#24

Justin, I'd say we can't really say yet. There's a great deal of unpredictability regarding what 2021 holds for us with COVID. I don't believe we're able to offer any sense of scale at this moment.

Justin Lake

analyst
#25

We're aware of the advocacy shortfall — I believe that's the $0.50 figure you mentioned. Your point is that these COVID-related expenses might reach that level or exceed it, based on how things unfold across the coming months and into next year.

Joel Ackerman

executive
#26

Well, you need to consider COVID from several angles. First, there are direct costs — those might stay level, might decline, or in theory might also rise. I'd characterize that as highly uncertain. Then there are the offsets: as things stand today, sequestration relief will disappear unless some new development occurs, and that's clearly going to be a headwind. The savings we've seen on benefits will probably also become a headwind once our teammates begin returning and receiving the care they require. T&E remains an open question; that's part of what drives the cost and offset figures. On top of all that, you must factor in the volume effect. Keep in mind, it compounds. The drag from Q2 and Q3 will persist as a headwind until those decreases hit their anniversary, and that's going to take some time. How mix gets affected is unclear. As Javier mentioned, it's turned out far better than we ever anticipated, but we can't predict what COVID will bring to the economy moving forward.

Justin Lake

analyst
#27

Alright, you brought up mix. From what I recall, the release stated that mix moved lower during the third quarter compared with Q2, or else it worked against you. Could you share additional detail about the size of that mix shift?

Javier Rodriguez

executive
#28

I'll take that one, Justin. Nothing much really jumped out regarding mix, so I'm unclear what source you're referring to there, but I wouldn't highlight anything that matters for your model.

Justin Lake

analyst
#29

All right. Perhaps I misunderstood that. So for my final question, I want to piggyback on what Kevin asked regarding Humana. Assuming they are in a network—and I realize you are in discussions with them—if they are in a network for 2021, you have already indicated that growth in Medicare Advantage will be slow and steady. Do you believe it is—I realize part of this hinges on whether you keep members, and from what I understand, Humana may have been compensating you somewhat above the typical rate, at least based on what they say. When you add everything up, do you think there is a chance Medicare Advantage remains positive, meaning it expands sufficiently to make up for what is lost with Humana? Do you think the net result is closer to neutral, or perhaps even a headwind, once all of it is combined?

Javier Rodriguez

executive
#30

Yes. Clearly, several elements are involved here. First is enrollment and whether we get it right that the increase is gradual. I believe, once again, that we will get that right. Regarding the contracting, as I mentioned, our contracts are comprehensive, and we believe we have placed it in the appropriate category. Once more, it depends on Humana, which is a fairly substantial participant. I believe this is factored into our guidance, and I do not think it will be anything that jumps out in your model as a significant increase or decrease. Those factors will fluctuate within a range that, in my view, will not be overly wide.

Justin Lake

analyst
#31

Got it. Thanks for the call.

Javier Rodriguez

executive
#32

Thank you.

Lisa Clive

analyst
#33

Hello. I have 2 questions. To begin, continuing from what was asked before, regarding the revenue, it was noted that the quarter-over-quarter shift largely stemmed from a drop in commercial revenue for treatment. You said those were essentially one-time unfavorable movements. The phrasing mentioned government payer mix, which came across as rather strange, and then there was a reduction in calcimimetic, which was more or less anticipated. I just wanted to revisit this to confirm nothing unusual is happening with patient mix. Especially, if there were some sort of headwind, that would seem strange since, from what I gather, the deaths you're observing among COVID patients are mostly older individuals. If anything, that should provide a mild tailwind for patient mix. Some clarity on this would be helpful. For my 2nd question, concerning your additional COVID expenses related to your teammates, how much of that, or what share, went toward childcare, and might that drop significantly now that schools have largely returned to in-person and, hopefully, will stay that way?

Joel Ackerman

executive
#34

Yes. Lisa, I'll take the RPT item. The government aspect is a seasonal occurrence that usually takes place in Q3 tied to Medicare re-enrollment; as for the commercial side, you're correct that COVID provides a small tailwind; it aids our commercial mix somewhat, since mortality disproportionately affects older patients, who are more likely to be on Medicare.

Javier Rodriguez

executive
#35

The second part was around the cost of childcare.

Lisa Clive

analyst
#36

Yeah.

Javier Rodriguez

executive
#37

Honestly, watching how things unfold with the schools is going to be quite interesting, I believe. I'm not sure — my own children, plus what our teammates tell me, suggest it has been extremely fluid. We've seen a broad spectrum, from folks who stayed home the entire time, all the way to being in school full-time, with plenty of variations in between. There have been stops, restarts, and conclusions. Our aim is to back our teams and build the tools that let them head to work. We're financing certain safety nets and various programs, and our hope is that those have them covered. Naturally, should the situation grow materially worse and we return to a truly acute shutdown, everyone will find themselves in the same difficult spot. We've readied ourselves for that. Once more, it all falls within the bandwidth of how this pandemic behaves.

Lisa Clive

analyst
#38

Alright, it seems the additional assistance is still required by people. At this stage, the expenses likely aren't going down from where you stand.

Javier Rodriguez

executive
#39

Lisa, here's the thing — how the education system gets managed varies across regions of the country. We're observing separate clusters when it comes to costs, demand, and limits placed on our team members, plus the way they're managing childcare. Things have been uneven and area-specific.

Joel Ackerman

executive
#40

Right. Speaking more generally, when we consider how COVID will affect Q4, what we expect is that it will resemble Q2 more than Q3, and it will probably be a negative rather than the positive that Q3 delivered.

Lisa Clive

analyst
#41

Alright, that's quite useful. Thanks.

Javier Rodriguez

executive
#42

My apologies — just to make it clear, that covers all of it.

Joel Ackerman

executive
#43

Correct. Yes.

Javier Rodriguez

executive
#44

This isn't just about looking at things through the limited perspective of schooling.

Lisa Clive

analyst
#45

Yes.

Javier Rodriguez

executive
#46

Thank you.

Pito Chickering

analyst
#47

Hello, everyone, and thank you for allowing me to ask. I have a handful of questions regarding your Q4 outlook. In Q3, it appears you achieved a 15% operating income margin even with $66 million in advocacy costs, yet your guidance points to margins falling in Q4. Could you help me understand, perhaps put some numbers around, what's baked into that Q4 margin? Also, I'd appreciate more clarity on the favorable COVID effect during Q3 — I didn't quite follow that part.

Joel Ackerman

executive
#48

Regarding Q4, I'd say two factors are at play. The first is COVID. As I noted earlier, COVID contributed a positive, roughly $20 million to $30 million to OI in Q3; when we look at Q4, we anticipate a pattern closer to Q2. A significant swing the other way. That accounts for the largest portion of the drop from Q3 to Q4; on top of that, we expect certain seasonal influences and other items that will probably push Q4's underlying earning power somewhat lower. COVID stands out as the primary reason behind the margin contraction we described. Turning to Q3 and how it ties to COVID, what stands out is a series of favorable effects on the P&L tied to COVID. The most notable ones I'd highlight include sequestration, suspension, reduced T&E, reduced benefit costs, and the direct costs incurred in Q2 mostly disappeared. They didn't vanish entirely, but for the most part they disappeared. Consequently, those offsets exceeded the direct costs, which explains why COVID ended up as a net positive during that quarter.

Pito Chickering

analyst
#49

All right. Suppose we use the midpoint of the operating guidance you gave for the fourth quarter — let's call it $420 million — and treat that as applying to 2021, then factor in the $50 million COVID swing; roughly speaking, the underlying run rate ought to land around 470. If we put that on an annualized basis, would that be the way you'd frame the base as we head into 2021, on the assumption that COVID eases, or is there something that might throw that reasoning off in one direction or the other?

Joel Ackerman

executive
#50

Yeah. Look, Q4 carries a great deal of uncertainty where COVID is concerned, so I'd rather not be too exact. If what you want is a jumping-off point for building a model for next year, then taking the full year and making adjustments for the three major items — calcimimetics, ballot initiatives, and COVID — strikes me as the correct approach to arrive at the starting point for a next-year model.

Pito Chickering

analyst
#51

Okay.

Joel Ackerman

executive
#52

Joel Ackerman here. Let me flag something — I mentioned calcimimetics, but keep in mind we've described that category as approximately level during 2021 compared with 2020. The reason I'm bringing this up is that back in 2020, we treated it as non-recurring, whereas in 2021 it's going to be a recurring piece of our OI.

Pito Chickering

analyst
#53

All right. A second follow-up from my side; word is that home dialysis keeps picking up speed. Can you help us put any kind of figure on the operating margin leverage tied to each 100 basis points of patients shifting out of in-center care and into home? What kind of effect does that have on your bottom line? Many thanks.

Joel Ackerman

executive
#54

Yeah. That figure hasn't been provided by us. This is a quite complex matter, and it shifts as time passes. Which patients are the ones transitioning from in-center to home matters, so as a rule we've avoided attempting to attach a particular number to it.

Pito Chickering

analyst
#55

So when you look at the shift toward home in general, that ends up lifting your net operating margin, is that right?

Joel Ackerman

executive
#56

That's right.

Pito Chickering

analyst
#57

All right, thank you very much.

Whit Mayo

analyst
#58

Hi, thanks. I'd like to build on that previous question, but from a slightly different angle. How does the Non-Acquired Treatment Growth profile differ between in-clinic and home? I realize home is expanding at a much quicker pace, as Pito mentioned, but if we took home out of the picture, what would in-clinic growth look like?

Joel Ackerman

executive
#59

Apologies, Whit, I'm having trouble. Well, to start with, that's a difficult figure to provide given COVID, since our NAG shifts around so significantly. Are you asking about right now, or are you asking about something like pre-COVID?

Whit Mayo

analyst
#60

Before the pandemic.

Joel Ackerman

executive
#61

The way we've described it in the past is that home is expanding at roughly five times the pace of in-center.

Whit Mayo

analyst
#62

So perhaps we could just build on that, and maybe a general guideline for how to think about the shift between in-clinic and home.

Joel Ackerman

executive
#63

My apologies, Whit, did I not?

Whit Mayo

analyst
#64

No, I suppose what I'm getting at is this — suppose enterprise-level NAG is expanding by 1%, while home is up 8% or 10%, then I figure we can circle back on that. That's okay. Perhaps I overlooked this before, but regarding the commercial revenue decline this quarter, was it simply routine payer settlements that worked to our disadvantage?

Joel Ackerman

executive
#65

Simply routine swings. Nothing notable there, nothing that I believe repeats at all or changes the way anyone should view our commercial rates down the road.

Whit Mayo

analyst
#66

Alright, perhaps one additional item — I’m not sure whether you provided this earlier and it slipped past me, but the calcimimetics RPT along with the cost per treatment.

Javier Rodriguez

executive
#67

Those I haven’t shared yet, though I have them right here. Just a moment; during Q3, the RPT for calcimimetics came to $6.31, while cost per treatment stood at $4.31. When you consider the OI generated by calcimimetics in Q3, that figure was roughly $15 million.

Whit Mayo

analyst
#68

All right. Regarding what we might see in Q4 — obviously, we're aware ASP has fallen quite a bit.

Javier Rodriguez

executive
#69

Right. We've flagged that 50 to 70 would sit at the top of the range. My sense is we can keep assuming we'll land close to the top of that range. It's even possible we come in slightly higher than it.

Whit Mayo

analyst
#70

All right, that's useful. Thank you, fellas.

Gary Taylor

analyst
#71

Hello, good morning. Joel, perhaps returning to the topic of home versus in-center. Since you called it a complicated question, I'll pose it in a slightly more complicated way. Regarding the home incremental margin you mentioned, are we talking about a percentage or dollars? If you consider a center that is operating and the contribution from an additional patient compared with, say, a fully loaded patient, does that alter your thinking about the answer? Does PD or home hemo affect how you respond?

Joel Ackerman

executive
#72

Yes; it holds true for percentage as well as dollars; as for the other items you mentioned, every one of those plays a role in it, and so do commercial mix and various other factors.

Gary Taylor

analyst
#73

All right. Okay. That's useful, I'd say. I believe I see the direction in which those move. I was simply checking the advocacy expense, which came to $66 million during the quarter. In 2Q, I believe those didn't matter much.

Joel Ackerman

executive
#74

Yes.

Gary Taylor

analyst
#75

Is that accurate? During the third quarter of 2019, twelve months back, my assumption would have been that those items were material. They weren't anywhere in the notes I have. Should you not have them available, I'll circle back on it.

Joel Ackerman

executive
#76

Gary, just to remind you, our advocacy expenses fall into a pair of categories as we see it. One figure, roughly $30 million, comes back annually, and that's not actually the piece we mean; it's already included within every other figure we report. What we mean is advocacy tied specifically to Prop 23, that California ballot initiative from 2018. During 2019, there was none. At present, we're in an even year.

Gary Taylor

analyst
#77

Okay

Joel Ackerman

executive
#78

issue.

Gary Taylor

analyst
#79

If I could, just 2 more quick ones. ETC hasn't gotten much airtime from you, plus it wasn't mentioned among your headwinds or tailwinds. What's your thinking on treatment choices for next year?

Javier Rodriguez

executive
#80

Thank you, Gary. I'll take that one. ETC was released, it removed certain items, introduced some enhancements, and we're quite grateful to the administration for listening to the community; clearly we'll put in a lot of effort to achieve their goals since those goals match ours, which means getting more individuals onto the proper modality and ensuring the greatest possible number of people are able to receive transplants. Should you want a figure to put into your model, truthfully it's somewhat early, though I'll rely on what CMS stated. According to them, it would deliver savings of $34 million across 6 years, and that applies to the whole industry. Take a third of that. From what I understand, it's somewhat gentler at the beginning, then takes a bit more toward the end. As you're able to see, those figures are easy to absorb.

Gary Taylor

analyst
#81

Understood. That's the final item. Do you have any perspective on the way DaVita could ultimately take part in CMS Direct Contracting? On the face of it, plenty of aspects make it sound like precisely the thing you've long been requesting from CMS on behalf of your patient population; it genuinely appears that maybe — I'm not certain how things would shake out regarding passive enrollment — but it appears an opening would exist for possibly doing some voluntary enrollment within your population. I'm confident your team has likely examined this already. Any big-picture views about it?

Javier Rodriguez

executive
#82

Indeed, you're completely correct that we keep looking into each possibility; we keep pursuing the Kidney Care Act, and we're assessing all of those voluntary models; rules get released as things progress, which makes them rather fluid. Some days we feel quite enthusiastic about a particular format, and then the rules arrive and it turns out either discouraging or more difficult for us to take part in. We keep assessing it, and we'll follow up with you after all of it is finalized. Just yesterday, in fact, regarding the voluntary models, the financial structure was released. It runs about 100 pages, so we're still working through it, but we'll return to you once we've reached a conclusion.

Gary Taylor

analyst
#83

Thank you.

Javier Rodriguez

executive
#84

Thank you.

John Ransom

analyst
#85

Hey there, good evening, folks. Let me sort of pull back and pose what might be a larger question. It appears the incentives line up when MA plans receive capitation from Medicare and then collaborate with you to capitate those high-risk patients. Of course, you brought eight years of experience with DaVita Medical around capitation. I suppose what isn't clear to me is this: will we remain trapped in fee-for-service territory 5,000 years down the road? Is progress simply going to crawl along at a glacial pace? What's blocking the path to pushing this toward a broader, more global conversation? It feels like we're frozen exactly where we stood five, 10 years back, given that 99.9% of your revenue continues to come purely from fee-for-service, and you've got these squabbles over a dollar here, a dollar there. So what's your take on that?

Javier Rodriguez

executive
#86

Thanks, John. Well, we're with you that a significant movement is underway at this moment. There's appetite, there's momentum, there's plenty of interest. These deals prove far more complicated to execute, establishing the baseline, establishing the incentives so they stretch across multiple years, which lets us make the investment. As you noted, it's taken some time, but I believe there's an intersection point of momentum right now. It takes two to tango, and it feels like the other side is willing, and we are ready. I think across the next couple of years, you're going to see a lot more of these deals come across.

John Ransom

analyst
#87

Thanks. One more thing from me: looking back at your most recent Analyst Day, when you set out those objectives, clearly COVID created plenty of disruption, plus there were some timing-related items. So if we take a broader view — comparing your assumptions at that point with what we now believe has shifted in a structural way for the business — which changes would you highlight, whether favorable or unfavorable, when we assess DaVita's earning potential?

Joel Ackerman

executive
#88

Sure, I'll handle that one. At the core, our margin improvement has come much further than we anticipated, and it arrived sooner than we expected possible. A portion of that traces to RPT, and another portion traces to how we manage costs. Regarding RPT, I can't really single out one particular item. Within the mix there's a rate component, across both commercial and Medicare, and that has driven better bad debt. It's fairly wide-ranging. In the same way, when it comes to costs, I believe our productivity execution has been excellent. We keep realizing gains; over on the pharma side, we've handled a number of the clinic expenses that aren't tied to people really effectively. On the whole, pushing the OI margin higher has mattered a great deal. And beneath the OI line, our interest expenses have dropped substantially, plus we've repurchased additional shares at a quicker pace than anticipated. There's no single secret solution involved. It's fairly even throughout the income statement, yet we couldn't be prouder. In my view the performance has been solid, and we're genuinely thrilled about our current position.

John Ransom

analyst
#89

Suppose we looked at things the way they used to be — same payer mix, same environment — would you still be engaged in bitter, take-no-prisoners battles over commercial agreements and treatment revenue? Medicare isn't part of this question, right, or have we moved beyond that stretch of acrimony and those regrettable talks from several years back?

Javier Rodriguez

executive
#90

Honestly, John, what analysts and other folks pick up on is strange, since when everything is said and done, those discussions are usually pretty constructive and productive. Perhaps the thing is that you only hear about the extreme cases, the ones that turn really nasty. Typically, everyone is aiming toward one shared result: can we do more for patients? Can we provide the strongest network, and can we do it in a manner that bends or betters the cost curve? We come to the table aligned on those objectives, and every so often it just turns out that someone — whether it's us — gets seen as greedy, or the other side gets seen that way, and so no agreement is reached. If you went back and tallied up how many of those turned so hostile and protracted, you could count them on one hand. It may simply be that we hold onto those memories because they stand out so much.

John Ransom

analyst
#91

Great. All right. Thank you.

Javier Rodriguez

executive
#92

Thank you.

Matt Larew

analyst
#93

Good afternoon. Hey, Joel, perhaps you could give it another shot regarding how COVID trends played out between the third and fourth quarters, and I realize putting hard numbers on this isn't easy. Speaking directionally, I'm still working through in my own mind which of those elements would flip as far as being a plus or a minus when moving from Q3 to Q4, and it might be useful just to know which ones you see reversing?

Joel Ackerman

executive
#94

Sure. There's somewhat more on the direct cost side. There's somewhat more of an effect from fewer treatments being performed, and somewhat from decreases in the offset. All three of those buckets are contributing.

Matt Larew

analyst
#95

All right. Javier, there's a fascinating development regarding the Kidney Smart platform, and the metrics coming out of it look solid. I'm just wondering, where is adoption showing up the most? I'd also be curious what the economics might look like, if there are any at all, when you work with partners to offer that platform.

Javier Rodriguez

executive
#96

There are no economics involved. It costs nothing, and the entire community can access it, so anybody is able to use it. The overarching expectation is, naturally, that individuals can make a transition, engage in modality planning, and in lots of cases simply become psychologically prepared for the lifestyle shift that lies ahead. It is quite literally a present to the community, and ideally it assists people in moving toward what will probably be an enormous lifestyle transformation lasting a lifetime. We take great pride in it. Should you ever visit it, it's extremely thorough yet simple to grasp, and we believe it's generating genuine change within the community.

Matt Larew

analyst
#97

Fair enough. Thank you.

Javier Rodriguez

executive
#98

Thank you.

Kevin Fischbeck

analyst
#99

Kevin, thanks. A couple of quick follow-ups from my side. I appreciate the detail on the EPS guidance, but could you perhaps walk through the components a bit further? On the Operating Income increase, can we think about what portion comes from revenue growth and what portion comes from further margin improvement from this point? You're already beyond the margin target you set for 2022. I'm trying to determine whether additional room exists there.

Javier Rodriguez

executive
#100

Javier, I'd say it's somewhat early for us to go into that degree of specificity. Things can clearly unfold in various ways as time passes, subject to certain industry dynamics. Some capital allocation dynamics could matter too. My sense is we'll stay with just OI and EPS.

Kevin Fischbeck

analyst
#101

All right. The next thing I wanted to ask about is that you brought up Humana in connection with a capitated arrangement, or a value-based one, I believe. Generally, there's far greater appetite for pursuing arrangements of this kind. What's the right frame for us when it comes to how profitable such contracts are? I don't mean Humana specifically, just broadly. Once you sign these, do you go in expecting to use them as a means of preserving the economics you currently get from those patients? Or do you see it as: because you're bearing risk, you ought to be compensated more and earn more from that patient, simply for taking on risk beyond the old fee-for-service model?

Javier Rodriguez

executive
#102

That's a reasonable thing to ask, Kevin, and the truth is there's no easy response. Where you begin is important, and so is the structure's baseline. With certain of these, you need to put money in at the front in order to see the returns later on. There isn't a clean, straightforward response to it. Broadly, I believe the goal for all of us here is to bend the cost curve, and if a larger pool can be created for us to operate in and take part in, then ideally we're able to take part in it. Some investment at the front is required — that's the way I look at it.

Kevin Fischbeck

analyst
#103

Alright. My understanding is that historically, you ran into problems with certain aspects of how government programs are set up, where there's this persistent recalibration of the baseline. When you achieve cost reductions, your payments get reduced. That's how a few of the earlier demos operated. What I'm assuming is that discussions with managed care are more workable, I suppose, given how they're structured, in that they're more closely linked to the total MA rate instead of the savings you generate.

Javier Rodriguez

executive
#104

Yes. Typically with MA, naturally, there's risk adjustment, and because of that, you're able to get familiar with the patient and how ill they are. With the other government programs, it's felt somewhat like a black box, and then suddenly when the program wraps up and following X amount of months, you learn that you were rebased. That makes it genuinely difficult to predict how aggressively you should invest, and that's the greatest difficulty we've encountered with the government programs. With MA it's the reverse, since you can truly grasp your risk, you can grasp how much you're investing along with the potential gains and losses.

Kevin Fischbeck

analyst
#105

All right. Great. Thank you.

Javier Rodriguez

executive
#106

Thank you.

Lisa Clive

analyst
#107

Hello. I have a single additional inquiry regarding home dialysis, and maybe another perspective on how it affects profits. When a patient receives treatment in a clinic compared to at home, is there a significant variation in how long they remain covered by private insurance? My assumption is that those undergoing dialysis at home are able to keep working. Does that have a meaningful effect on how many months they continue to be privately insured?

Javier Rodriguez

executive
#108

In short, no — there is nothing extraordinary about home versus private insurance. There could be a pre-selection bias, in that a greater number of employed individuals will choose home. If you remember from capital markets, another crucial point to keep in mind is that around 85% of our patients who dialyze at home receive treatment in a center at some stage, whether at the beginning, at the end, or even in the course of their care. We have always debated whether some of these dynamics you are attempting to reach economically, or regarding the duration of private pay, etc., stem from the modality or from the patients who selected the modality. We do not know.

Lisa Clive

analyst
#109

Okay. Thanks.

Javier Rodriguez

executive
#110

Thank you.

Javier Rodriguez

executive
#111

Alright. Thanks, Michelle. I'll offer a few final thoughts. It's obvious that conditions are tough right now, but I want once more to express appreciation for how committed, how compassionate, and how professional our teams are. Second, the promises we made to you have been fulfilled earlier than planned, and we're in a genuinely strong spot to achieve the earnings growth we've targeted across multiple years. Take care of yourselves, and thanks for your interest in DaVita.

Operator

operator
#112

Thanks. That wraps up the conference call for today. At this point, you're free to go ahead and disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.